MUC16 and neoplasm: To further investigate the anti-tumor potential of ch5E6 in preclinical KrasG12D/+; TP53R172H/+; Pdx-1-Cre (KPC) and KrasG12D/+; TP53R172H/+; Ad-Cre (KPA) mouse models of pancreatic40 and lung cancer41 respectively, we developed organoids from tumors of these animals and first established ch5E6 reactivity for Muc16 expression (Fig. 4b) which was further confirmed by IHC and immunoblotting analysis on KPC and KrasG12D; TP53R172H; Pdx-1cre; Muc16-/- (KPCM) mice tumors and cell lysates (Supplementary Fig. 5a, b).